INHERITED DISORDERS OF PLATELETS FUNCTION, IDIOPATHIC THROMBOCYTOPENIC PURPURA AND THROMBOTIC THROMBOCYTOPENIC PURPURA

Surface Glycoproteins of Platelets and Their Roles

1. Glycoprotein Ib-IX-V Complex (GPIb-IX-V)

The GPIb-IX-V complex is crucial for platelet adhesion to the damaged vascular wall. It consists of four subunits: GPIbα, GPIbβ, GPV, and GPIX. The GPIbα subunit has a binding site for von Willebrand factor (vWF), which mediates the capture of platelets at injury sites. This complex plays a leading role in hemostasis by facilitating the initial attachment of platelets to exposed collagen in the extracellular matrix.

2. Glycoprotein IIb/IIIa Complex (GPIIb/IIIa)

This integrin complex is essential for platelet aggregation and adhesion to endothelial surfaces. It interacts with fibrinogen, allowing platelets to stick together and form a primary platelet plug during clot formation. The activation of this complex can be triggered by various factors such as ADP or thrombin, leading to conformational changes that enable it to bind fibrinogen effectively.

3. Glycoprotein VI (GPVI)

GPVI serves as a receptor for collagen and is involved in collagen-induced platelet activation and adhesion. It plays a significant role in procoagulant activity, contributing to thrombin generation and fibrin formation during clotting processes. The activation pathway involves interactions with other proteins like Src kinases and phospholipase C.

4. Glycoprotein Ia/IIa Complex (GPIa/IIa)

This complex acts as a receptor for collagen types I and IV, stabilizing platelets upon interaction with these collagen fibers. It consists of two subunits: α2 (GPIa) and β1 (GPIa). Variability in its expression can influence an individual’s susceptibility to cardiovascular events such as myocardial infarction or ischemic stroke.

5. Glycoprotein IV (GPIV)

Although less characterized than others, GPIV is thought to function similarly to GPVI in terms of collagen binding and may also play a role in platelet activation during hemostatic responses.

In summary, these surface glycoproteins are integral to the processes of platelet adhesion, aggregation, and overall hemostatic function, ensuring that bleeding is effectively controlled following vascular injury.

Pathogenesis of Bernard-Soulier Syndrome

Bernard-Soulier syndrome (BSS) is primarily caused by genetic mutations that affect the glycoprotein Ib-IX-V complex (GPIb). This complex is essential for platelet adhesion to the damaged vascular endothelium, as it serves as a receptor for von Willebrand factor (vWF). In individuals with BSS, mutations in the genes encoding components of this complex—specifically GP1b-alpha, GP1b-beta, and GP9—lead to either a complete absence or decreased expression of GPIb on the surface of platelets. As a result, platelets cannot effectively bind to vWF, which is crucial for initiating the clotting process. This deficiency leads to impaired platelet aggregation and an increased tendency for bleeding.

The inheritance pattern of BSS is autosomal recessive, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to manifest symptoms. Carriers of one normal and one mutated gene typically do not exhibit symptoms but can pass the abnormal gene to their offspring.

Laboratory Findings in Bernard-Soulier Syndrome

Diagnosis of BSS involves several laboratory tests:

1. Complete Blood Count (CBC): This test typically reveals thrombocytopenia (low platelet count) and may show macrothrombocytes (abnormally large platelets).
2. Peripheral Smear: A microscopic examination will demonstrate giant platelets and irregularly shaped platelets.
3. Bleeding Time: Prolonged bleeding time is common due to impaired platelet function.
4. Platelet Aggregation Studies: These studies reveal that platelets do not aggregate in response to ristocetin even when normal plasma is added; however, they will aggregate normally in response to other agonists such as adenosine diphosphate (ADP), epinephrine, and collagen.
5. Flow Cytometry: This technique measures the expression levels of GPIb on the surface of platelets, confirming its deficiency.

Pathogenesis of Thrombasthenia

Thrombasthenia refers to a group of inherited disorders characterized by defective platelet function despite normal platelet numbers. The most well-known form is Glanzmann thrombasthenia, which results from mutations affecting the glycoprotein IIb/IIIa complex on platelets. This complex is critical for platelet aggregation because it binds fibrinogen and facilitates cross-linking between activated platelets.

Similar to BSS, thrombasthenia follows an autosomal recessive inheritance pattern. Individuals with this condition have normal platelet counts but experience excessive bleeding due to their inability to form stable aggregates during hemostasis.

Laboratory Findings in Thrombasthenia

The laboratory findings associated with thrombasthenia include:

1. Complete Blood Count (CBC): Platelet counts are typically within normal ranges.
2. Bleeding Time: Prolonged bleeding time occurs due to defective aggregation.
3. Platelet Aggregation Studies: Unlike BSS, patients with thrombasthenia show no aggregation in response to all agonists including ADP and epinephrine but may respond normally to ristocetin when vWF is present.
4. Flow Cytometry: This test can be used to assess the expression levels of glycoprotein IIb/IIIa on platelets, confirming its deficiency or dysfunction.

In summary, both Bernard-Soulier syndrome and thrombasthenia are characterized by distinct pathophysiological mechanisms leading to impaired hemostasis; however, they differ significantly in their underlying genetic causes and specific laboratory findings.

Etiology of Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count (thrombocytopenia) and an increased tendency to bleed. The etiology of ITP is not fully understood, but it is believed to involve an autoimmune process where the immune system mistakenly targets and destroys platelets. In adults, ITP can be primary (idiopathic) or secondary to other conditions such as infections (e.g., HIV, hepatitis), autoimmune diseases (e.g., lupus), or certain medications. In children, ITP often follows a viral infection and is usually self-limiting.

Pathogenesis of ITP

The pathogenesis of ITP involves several key mechanisms:

1. Autoantibody Production: In many cases, patients develop antibodies against their own platelets, particularly targeting glycoprotein IIb/IIIa and glycoprotein Ib/IX complexes on the platelet surface.
2. Splenic Sequestration: The spleen plays a crucial role in filtering blood and removing damaged or antibody-coated platelets. In ITP, the spleen may sequester more platelets than normal due to the presence of these antibodies.
3. Bone Marrow Dysfunction: Although platelet production may be normal or even increased in response to thrombocytopenia, the presence of autoantibodies can inhibit megakaryocyte maturation and function in the bone marrow.

Clinical Findings

The clinical presentation of ITP varies between adults and children:

• Adults: Patients may present with easy bruising, petechiae (small red or purple spots on the skin), prolonged bleeding from cuts, heavy menstrual periods (menorrhagia), and in severe cases, spontaneous bleeding from mucosal surfaces.
• Children: Pediatric patients typically present with similar symptoms but often have a more acute onset following a viral illness. Most children experience mild symptoms that resolve spontaneously within weeks to months.

Laboratory Results

Diagnosis of ITP is primarily based on laboratory findings:

1. Complete Blood Count (CBC): A CBC will show isolated thrombocytopenia with normal white blood cell and red blood cell counts.
2. Peripheral Blood Smear: This may reveal large platelets (megakaryocytes) indicating increased platelet turnover.
3. Bone Marrow Biopsy: This is not routinely performed but may be indicated if there is suspicion for other causes of thrombocytopenia; it typically shows increased megakaryocytes in cases of primary ITP.
4. Tests for Secondary Causes: These include serological tests for infections like HIV or hepatitis, autoimmune markers for conditions like lupus, and medication history.

Patient Management

Management strategies for ITP depend on the severity of symptoms and platelet counts:

1. Observation: In asymptomatic patients with mild thrombocytopenia (>30 x 10^9/L), observation without treatment may be appropriate.
2. Medications:
   • Corticosteroids: First-line treatment for adults; they help reduce immune-mediated destruction of platelets.
   • Intravenous Immunoglobulin (IVIG): Used in cases requiring rapid increase in platelet count or during surgery.
   • Anti-D immunoglobulin: Effective in Rh-positive patients who are also Rh-positive; it works by promoting splenic clearance of antibody-coated red blood cells rather than platelets.
3. Surgical Options:
   • Splenectomy: Considered for chronic cases unresponsive to medical therapy; removal of the spleen can lead to significant increases in platelet counts as it is a major site of platelet destruction.
4. Newer Therapies:
   • Medications such as thrombopoietin receptor agonists (e.g., eltrombopag) are used for chronic ITP when conventional treatments fail.

In pediatric cases where spontaneous recovery occurs frequently, management may focus on reassurance unless severe bleeding occurs.

In summary, both adult and pediatric forms of ITP share common features but differ significantly in etiology and management approaches due to differences in disease course and underlying causes.

Mechanism of Neonatal and Post-Transfusion Thrombocytopenia

Neonatal thrombocytopenia is defined as a platelet count of less than 150 × 10^9/L in neonates. It is a common condition observed in the neonatal intensive care unit (NICU), affecting approximately 20-35% of admitted patients. The mechanisms underlying neonatal thrombocytopenia can be multifactorial, including decreased production, increased destruction, or sequestration of platelets.

Decreased Platelet Production

In neonates, particularly those born prematurely or with low birth weight, there may be an inadequate production of platelets due to immature megakaryocyte development. Megakaryocytes are the bone marrow cells responsible for producing platelets. The process of megakaryocytopoiesis is significantly different in neonates compared to adults; thus, factors such as gestational age and maternal health can influence platelet production. For instance, conditions like maternal hypertension or intrauterine growth restriction (IUGR) can lead to lower platelet counts in neonates due to impaired hematopoiesis.

Increased Platelet Destruction

Another mechanism contributing to thrombocytopenia in neonates is increased destruction of platelets. This can occur due to various reasons:

1. Immune-mediated destruction: Conditions such as neonatal alloimmune thrombocytopenia (NAIT) arise when maternal antibodies target fetal platelets, leading to their destruction.
2. Sepsis and infection: Infections can activate the immune system and result in increased platelet consumption.
3. Disseminated intravascular coagulation (DIC): This serious condition can lead to both increased clotting and subsequent consumption of platelets.

Post-Transfusion Thrombocytopenia

Post-transfusion thrombocytopenia refers specifically to a decrease in platelet count following a transfusion of platelets or other blood components. The mechanisms behind this phenomenon include:

1. Dilutional Effect: When large volumes of blood products are transfused, especially in cases where multiple transfusions are necessary, the dilution effect can temporarily reduce the concentration of circulating platelets.
2. Immune Response: Similar to neonatal alloimmune thrombocytopenia, post-transfusion purpura (PTP) may occur when a patient develops antibodies against donor platelets after receiving transfusions. This immune response leads to rapid clearance and destruction of transfused platelets.
3. Sequestration: Following transfusion, some platelets may become sequestered in the spleen or other organs due to changes in circulation dynamics or immune reactions.
4. Thrombotic Microangiopathy: In rare cases, thrombotic microangiopathy can develop post-transfusion, leading to microvascular damage and subsequent thrombocytopenia.

Conclusion

Understanding these mechanisms is crucial for managing neonatal thrombocytopenia effectively and minimizing unnecessary platelet transfusions while addressing underlying causes.

Clinical Findings of Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the formation of small blood clots (thrombi) in blood vessels throughout the body, leading to a reduction in platelets (thrombocytopenia), hemolytic anemia, and potential damage to vital organs.

Thrombotic thrombocytopenic purpura (TTP) is characterized by a distinct set of clinical findings that arise from the formation of platelet-rich thrombi in the microvasculature. The classic clinical presentation includes:

1. Microangiopathic Hemolytic Anemia (MAHA): Patients typically present with signs of hemolytic anemia, which may include fatigue, pallor, and jaundice. Laboratory findings often reveal elevated lactate dehydrogenase (LDH) levels, low haptoglobin levels, and the presence of schistocytes on a peripheral blood smear.
2. Severe Thrombocytopenia: A hallmark of TTP is a significant reduction in platelet count, usually less than 30,000 platelets per microliter. This can lead to increased bleeding tendencies, such as petechiae or purpura.
3. Neurological Symptoms: Neurological manifestations can vary widely and may include headaches, confusion, seizures, or focal neurological deficits due to ischemia caused by microthrombi affecting cerebral circulation.
4. Renal Impairment: Renal involvement may manifest as elevated serum creatinine levels or proteinuria due to glomerular damage from microvascular obstruction.
5. Fever: Although not always present, fever can occur in some patients and may be indicative of systemic involvement.
6. Other Symptoms: Patients may also experience symptoms such as abdominal pain or nausea due to mesenteric ischemia resulting from thrombi in the gastrointestinal tract.

Laboratory Results in Thrombotic Thrombocytopenic Purpura

The laboratory evaluation for TTP focuses on confirming the diagnosis through specific tests:

1. ADAMTS13 Activity Level: Measurement of ADAMTS13 activity is crucial for diagnosing TTP. An activity level of less than 10% supports the diagnosis of TTP in appropriate clinical contexts. However, results may take several days if sent to an external laboratory.
2. Inhibitor Testing: In cases where immune-mediated TTP is suspected (iTTP), inhibitor tests can help distinguish between immune-mediated and congenital forms of TTP by detecting anti-ADAMTS13 autoantibodies.
3. Complete Blood Count (CBC): A CBC will typically show severe thrombocytopenia alongside evidence of hemolysis (elevated LDH and low haptoglobin).
4. Peripheral Blood Smear: The presence of schistocytes on a peripheral blood smear indicates microangiopathic hemolysis and supports the diagnosis.
5. Coagulation Studies: Coagulation studies are usually normal in TTP since it is not primarily a coagulopathy but rather a disorder related to platelet aggregation due to VWF multimers.
6. Renal Function Tests: Elevated serum creatinine levels indicate renal impairment associated with TTP.

In summary, the clinical findings associated with TTP include microangiopathic hemolytic anemia, severe thrombocytopenia, neurological symptoms, renal impairment, and potentially fever; while laboratory results typically reveal low ADAMTS13 activity levels along with signs consistent with hemolysis and thrombocytopenia.